title: Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?
abstract: Erythropoietin-stimulating agents (ESAs) are used in breast cancer patients with chemotherapy-induced anemia to alleviate anemia and in turn, reduce fatigue. These drugs may also decrease overall survival and increase the incidence of serious adverse effects such as thrombovascular events (TVEs). This review evaluates the evidence to date on administering ESAs to breast cancer patients with chemotherapy-induced anemia. Our findings suggest a clear need for well-designed clinical trials that follow current Food and Drug Administration (FDA) ESA label changes to guide clinical practice in an effort to reduce harm to these patients.
authors.affiliation: Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, School of Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Ireland, keladao@tcd.ie.
authors.forename: Olivia
authors.initials: O
authors.lastname: Kelada
authors.forename: Laure
authors.initials: L
authors.lastname: Marignol
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics